Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Monday 16 January, 2017

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 2894U
GlaxoSmithKline PLC
16 January 2017
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr M M Slaoui

b)

Position/status

Chairman, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$39.01

1539.029

$39.01

1707.721

$39.01

1955.582

d)

Aggregated information

 

Aggregated volume Price

 

 5,202.332

 

 

$39.01

 

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

  

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$39.01

92.739

 

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

  

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$39.01

230.627

$39.01

46.151

$39.01

388.469

$39.01

77.719

$39.01

599.548

  

d)

Aggregated information

 

Aggregated volume Price

 

 

1,342.514

 

$39.01

 

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D E Troy

b)

Position/status

SVP & General Counsel

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

  

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.01

953.928

$39.01

1058.486

$39.01

1228.038

 

 

d)

Aggregated information

 

Aggregated

volume Price

  

3,240.452

 

 

$39.01

  

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr K Slaoui

b)

Position/status

PCA of Dr M M Slaoui (Chairman, Global Vaccines)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

 

 

b)

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 January 2017 on ADSs held in the Company's 2009 Performance Share Plan.

c)

Price(s) and

volume(s)

Price(s)

Volume(s)

$39.01

27.931

$39.01

26.461

$39.01

25.012

 

d)

Aggregated information

 

Aggregated volume Price

 

 

79.404

 

$39.01

 

 

e)

Date of the transaction

2017-01-12

f)

Place of the transaction

 

n/a

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHQQLFFDFFEBBX

a d v e r t i s e m e n t